Evolus (EOLS) Twitter Followers Statistics 2024

6870%

1W 0.4% 1M 2.6% 3M 3.4%

Followers on Twitter.

Similar companies

Company		Twitter Followers
	Johnson & Johnson JNJ	247,394 0%
	Eli Lilly and Company LLY	142,695 0%
	Pfizer PFE	483,251 0%
	Astrazeneca AZN	299,488 0%
	AbbVie ABBV	79,518 0%

Month over Month

Followers on Twitter.

Nov 2024	692	2.5%
Oct 2024	710	0.8%
Sep 2024	716	2.4%
Aug 2024	699

How many users are following Evolus on Twitter?

Evolus has 687 followers on Twitter. This is down by -2% in the last 30 days.

Analyzing Twitter Followers, how is Evolus performing compared to its industry peers?

Evolus underperforms its industry peers when it comes to Twitter Followers, ranking dead last.

Why should an investor in Evolus track and monitor Twitter Followers?

Tracking Evolus' Twitter followers offers insights into its brand popularity and customer engagement. A growing follower count signals rising interest in Evolus' products, services and a positive brand image. This metric serves as both a measure of engagement and a crucial audience for marketing strategies. By comparing Evolus' Twitter following with competitors, we gain perspective on its market standing. Although a singular aspect, Twitter followership, when combined with financial and operational data, contributes to a comprehensive understanding of Evolus' overall performance.

How does the current number of Twitter followers impact Evolus' brand presence and market influence?

With fewer than 1,000 followers, Evolus' Twitter account is in its growth phase, focusing on building its audience. This suggests a niche but potentially dedicated following, important for targeted engagement.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.